MCID: OCL009
MIFTS: 60

Ocular Cancer

Categories: Neuronal diseases, Cancer diseases, Eye diseases

Aliases & Classifications for Ocular Cancer

MalaCards integrated aliases for Ocular Cancer:

Name: Ocular Cancer 12 15
Eye Carcinoma 12 15 73
Eye Neoplasms 44 73
Eye Cancer 55 43
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 73
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Eye Neoplasm 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 35 190.8
MeSH 44 D005134
NCIt 50 C3030 C6079

Summaries for Ocular Cancer

MedlinePlus : 43 Cancer of the eye is uncommon. It can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. If the cancer starts inside the eyeball it's called intraocular cancer. The most common intraocular cancers in adults are melanoma and lymphoma. The most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. Cancer can also spread to the eye from other parts of the body. Treatment for eye cancer varies by the type and by how advanced it is. It may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to retinoblastoma and eye carcinoma in situ, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include the eye, eye and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises_from the tissues that cover structures located in the eye.

Wikipedia : 76 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 retinoblastoma 27.6 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
2 eye carcinoma in situ 11.9
3 vulvar adenocarcinoma 11.1 RB1 TP53
4 zika virus infection 11.0 MDM2 TP53
5 spindle cell lipoma 11.0 CDK4 MDM2 RB1
6 malignant fibrous histiocytoma of bone 11.0 CDK4 MDM2 MYC
7 glioblastoma proneural subtype 10.9 CDK4 CDK6
8 breast papillomatosis 10.9 CCND1 CDKN2A
9 ring chromosome 7 10.9 CDK4 MDM2 TP53
10 undifferentiated embryonal sarcoma of the liver 10.9 CDK4 MDM2
11 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
12 hepatic angiomyolipoma 10.9 MYC RB1
13 venous hemangioma 10.9 MYC POU5F1 SOX2
14 infiltrating angiolipoma 10.9 CDK4 CDKN2A MDM2
15 unilateral retinoblastoma 10.9 RB1 RBL1
16 periosteal osteogenic sarcoma 10.9 CDK4 MDM2 TP53
17 uterine corpus serous adenocarcinoma 10.9 BRCA2 TP53
18 atypical lipomatous tumor 10.9 CDK4 CDKN2A MDM2
19 well-differentiated liposarcoma 10.9 CDK4 CDKN2A MDM2
20 fallopian tube carcinoma 10.9 BRCA2 MYC TP53
21 small cell sarcoma 10.9 CDK4 MDM2 TP53
22 embryonal sarcoma 10.9 CDK4 MDM2 TP53
23 ewing's family of tumors 10.9 CDK4 CDKN2A RB1
24 synchronous bilateral breast carcinoma 10.9 BRCA2 CCND1 TP53
25 actinic cheilitis 10.8 CDKN1A MDM2 TP53
26 megaesophagus 10.8 CDKN2A MYC TP53
27 connective tissue cancer 10.8 CDK4 MDM2 TP53
28 glycogen-rich clear cell breast carcinoma 10.8 BRCA2 CDKN2A TP53
29 mutagen sensitivity 10.8 BRCA2 CCND1 TP53
30 myxoid liposarcoma 10.8 CDK4 MDM2 TP53
31 tetraploidy 10.8 BRCA2 TP53
32 histiocytoma 10.8 CDK4 MDM2 TP53
33 oral leukoplakia 10.8 CCND1 CDKN2A TP53
34 periosteal chondrosarcoma 10.8 CDK4 CDKN2A MDM2 RB1
35 gallbladder adenoma 10.8 CDKN2A RB1
36 endometrial squamous cell carcinoma 10.7 CCND1 CDK6 CDKN2A
37 ductal carcinoma in situ 10.7 BRCA2 CCND1 TP53
38 encephalocraniocutaneous lipomatosis 10.7
39 intraocular lymphoma 10.7
40 fibrosarcoma of bone 10.7 CDK4 CDKN2A MDM2 MYC
41 inflammatory myofibroblastic tumor 10.7 CCND1 MDM2 TP53
42 leiomyosarcoma 10.7 CDK4 MDM2 TP53
43 gliosarcoma 10.7 CDK4 RB1 TP53
44 male reproductive organ cancer 10.7 CCND1 MYC TP53
45 gastrointestinal system benign neoplasm 10.7 CCND1 CDKN2A TP53
46 extramedullary plasmacytoma 10.7 CCND1 CDKN1A IL2
47 penile cancer 10.7 CCND1 CDKN2A TP53
48 pharynx cancer 10.7 CCND1 CDKN2A TP53
49 central nervous system germ cell tumor 10.7 POU5F1 SOX2
50 chondromyxoid fibroma 10.7 CCND1 CDKN1A CDKN2A

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

GenomeRNAi Phenotypes related to Ocular Cancer according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.46 CDK2 MDM2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.46 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.46 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.46 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.46 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.46 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.46 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.46 CDK2 MDM2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.46 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.46 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.46 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.46 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.46 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.46 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.46 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.46 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.46 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.46 CCND1 CDK2 MDM2 MYC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.46 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.46 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.46 CDK2 MDM2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.46 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.46 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.46 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.46 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.46 CDK2
27 Decreased viability GR00221-A-1 10.36 CDK6 CDKN1B CDKN2A MYC RBL1 RBL2
28 Decreased viability GR00221-A-2 10.36 CDK6 RBL1
29 Decreased viability GR00221-A-3 10.36 CDKN2A MYC
30 Decreased viability GR00221-A-4 10.36 CDK6 CDKN2A SOX2
31 Decreased viability GR00301-A 10.36 CDK6
32 Decreased viability GR00402-S-2 10.36 CDK6 CDKN1B CDKN2A MYC RBL1 RBL2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 CDKN1A CDK2 CDKN2A BRCA2 TP53 RB1
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 CCND1 CDKN1A CDK2 CDKN2A BRCA2 TP53
35 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.63 BRCA2 CDKN1A CDKN1B CDK2 TP53 MDM2
36 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 CDK4 CDK6 CDK2 BRCA2 RBL1

MGI Mouse Phenotypes related to Ocular Cancer:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 IL2 E2F4 POU5F1 MYC MDM2 RBL1
2 endocrine/exocrine gland MP:0005379 10.58 GNAQ MDM2 E2F4 IL2 POU5F1 MYC
3 behavior/neurological MP:0005386 10.56 E2F4 IL2 GNAQ MDM2 MYC RBL1
4 growth/size/body region MP:0005378 10.55 E2F4 IL2 GNAQ MDM2 MYC RBL1
5 cardiovascular system MP:0005385 10.53 E2F4 IL2 GNAQ MYC MDM2 RBL1
6 hematopoietic system MP:0005397 10.53 IL2 GNAQ E2F4 POU5F1 MYC MDM2
7 homeostasis/metabolism MP:0005376 10.52 E2F4 IL2 GNAQ MDM2 MYC RBL1
8 embryo MP:0005380 10.51 E2F4 POU5F1 MYC MDM2 RBL1 RB1
9 immune system MP:0005387 10.51 IL2 GNAQ E2F4 MYC MDM2 RBL1
10 integument MP:0010771 10.5 GNAQ E2F4 POU5F1 MYC MDM2 RBL1
11 digestive/alimentary MP:0005381 10.49 IL2 E2F4 POU5F1 MYC MDM2 RBL1
12 mortality/aging MP:0010768 10.49 IL2 GNAQ E2F4 MYC MDM2 RBL1
13 neoplasm MP:0002006 10.41 IL2 E2F4 MYC MDM2 RBL1 RB1
14 craniofacial MP:0005382 10.4 E2F4 GNAQ MDM2 MYC RBL1 RB1
15 liver/biliary system MP:0005370 10.37 IL2 POU5F1 MYC MDM2 RB1 RBL1
16 nervous system MP:0003631 10.36 GNAQ MYC MDM2 RBL1 RB1 POU5F1
17 muscle MP:0005369 10.34 GNAQ MYC MDM2 RBL1 RB1 SOX2
18 hearing/vestibular/ear MP:0005377 10.28 E2F4 GNAQ MYC RBL1 RB1 SOX2
19 normal MP:0002873 10.25 E2F4 GNAQ MYC MDM2 RBL1 RB1
20 reproductive system MP:0005389 10.21 IL2 E2F4 POU5F1 MYC MDM2 RBL1
21 limbs/digits/tail MP:0005371 10.19 GNAQ MYC MDM2 RB1 BRCA2 RBL2
22 adipose tissue MP:0005375 10.18 MYC RB1 ABCG2 RBL1 TP53 CDKN1B
23 no phenotypic analysis MP:0003012 10.17 IL2 CDKN2A MYC MDM2 RBL1 RB1
24 pigmentation MP:0001186 10.02 GNAQ MYC MDM2 RB1 SOX2 CDK4
25 renal/urinary system MP:0005367 10.02 GNAQ MDM2 RB1 ABCG2 RBL2 RBL1
26 respiratory system MP:0005388 9.93 E2F4 IL2 GNAQ RBL1 RB1 CCND1
27 skeleton MP:0005390 9.8 E2F4 GNAQ MYC MDM2 RBL1 RB1
28 vision/eye MP:0005391 9.4 IL2 RBL1 RB1 CCND1 SOX2 RBL2

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
7
Nicotine Approved Phase 4 54-11-5 942 89594
8 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 4,Phase 2,Phase 1,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
16 Antifungal Agents Phase 4,Phase 2,Phase 1,Not Applicable
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18 Cytochrome P-450 Enzyme Inhibitors Phase 4
19
Hydroxyitraconazole Phase 4
20 Steroid Synthesis Inhibitors Phase 4
21 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
23
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
24
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
25
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
26
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
27
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
28
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
29
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
30
Topotecan Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 119413-54-6, 123948-87-8 60700
31
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
33
Fotemustine Experimental, Investigational Phase 3
34 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Micronutrients Phase 3,Phase 2
38 Trace Elements Phase 3,Phase 2
39 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
40 O(6)-benzylguanine Phase 3,Not Applicable
41 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Anti-Infective Agents, Local Phase 3,Phase 2
43 cadexomer iodine Phase 3,Phase 2,Phase 1
44 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
45 Anesthetics Phase 3,Phase 2,Not Applicable,Early Phase 1
46 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
48 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
49
Ibuprofen Approved Phase 1, Phase 2 15687-27-1 3672
50
Tramadol Approved, Investigational Phase 1, Phase 2 27203-92-5 33741

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
2 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3 carboplatin periocular injection;chemotherapy
6 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
7 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
8 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
9 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
10 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3 carboplatin;vincristine sulfate
11 Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma Completed NCT00072384 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
12 Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma Recruiting NCT03475121 Phase 3
13 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
14 Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Recruiting NCT01906814 Phase 3 3 cycles chemotherapy;6 cycles chemotherapy
15 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
16 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine + Topotecan;Vincristine + Carboplatin + Etoposide;Vincristine + Cyclophosphamide + Doxorubicin;Vincristine+Carboplatin+Etoposide
17 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
18 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
19 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 cisplatin;cyclophosphamide;etoposide;carboplatin;vincristine sulfate;thiotepa
20 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
21 Pain Relief - Tramadol Versus Ibuprofen Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
22 Efficacy Study of Lucentis in the Treatment of Retinoblastoma Unknown status NCT01899066 Phase 2 Lucentis, chemotherapy;chemotherapy
23 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
24 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
25 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
26 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
27 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
28 Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Unknown status NCT00179920 Phase 2 Carboplatin;VP-16
29 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
30 Study of D-Methadone in Patients With Chronic Pain Completed NCT00588640 Phase 1, Phase 2 d-Methadone;D-methadone;placebo
31 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
32 Melanoma Vaccine With Peptides and Leuprolide Completed NCT00254397 Phase 2 Leuprolide
33 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
34 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
35 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
36 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
37 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
38 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
39 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
40 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
41 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
42 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
43 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
44 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
45 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
46 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
47 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
48 Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Completed NCT00901238 Phase 1, Phase 2
49 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
50 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Cancer:

19
The Eye

MalaCards organs/tissues related to Ocular Cancer:

41
Eye, Liver, Bone, Bone Marrow, Skin, B Cells, Colon

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show all 17)
# Title Authors Year
1
Antonio Scarpa (1752-1832) and his study on ocular cancer. ( 29552793 )
2018
2
The beginning of using X-rays and the evolution of equipment for the treatment of ocular cancer. ( 28315914 )
2017
3
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. ( 27061559 )
2016
4
TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. ( 25834817 )
2015
5
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. ( 23441619 )
2013
6
The pathology of ocular cancer. ( 23154492 )
2013
7
Id2 deficiency promotes metastasis in a mouse model of ocular cancer. ( 20127274 )
2010
8
Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. ( 23181152 )
2010
9
Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer. ( 19098995 )
2008
10
A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. ( 17082795 )
2007
11
Non-cancerous ophthalmic clues to non-ocular cancer. ( 12431692 )
2002
12
Non-ocular cancer in relatives of retinoblastoma patients. ( 2789942 )
1989
13
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. ( 3356485 )
1988
14
Non-ocular cancer in hereditary retinoblastoma survivors and relatives. ( 3587888 )
1987
15
Non-ocular cancer in retinoblastoma survivors. ( 2837050 )
1987
16
Photodynamic therapy of human ocular cancer. ( 2956549 )
1987
17
Recent trends in the treatment of intra-ocular cancer. ( 13790869 )
1960

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9
(show all 45)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 14
2 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 14
3 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 14
4 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 14
5 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 14
6 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 14
7 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 14
8 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 14
9 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 14
10 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 14
11 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 14
12 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 14
13 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 14
14 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 14
15 COSM317962 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 14
16 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 14
17 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 14
18 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 14
19 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 14
20 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 14
21 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 14
22 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 14
23 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 14
24 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 14
25 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 14
26 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 14
27 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 14
28 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 14
29 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 14
30 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 14
31 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 14
32 COSM5700369 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 14
33 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 14
34 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 14
35 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 14
36 COSM5686463 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 14
37 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 14
38 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 14
39 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 14
40 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 14
41 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 14
42 COSM5700368 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 14
43 COSM5686462 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 14
44 COSM5668651 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 14
45 COSM5025108 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 14

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F4
2
Show member pathways
14.03 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
3
Show member pathways
13.91 CDK2 CDKN1A CDKN1B CDKN2A E2F4 MDM2
4
Show member pathways
13.9 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN1B
5
Show member pathways
13.62 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
6
Show member pathways
13.32 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
7
Show member pathways
13.23 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
8
Show member pathways
13.19 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
9
Show member pathways
13.18 CDK2 CDKN1A CDKN1B CDKN2A E2F4 MDM2
10
Show member pathways
13.1 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
11 13.06 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
12
Show member pathways
13.01 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
13
Show member pathways
13.01 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14
Show member pathways
12.96 CCND1 CDK2 CDK4 CDK6 CDKN1B IL2
15
Show member pathways
12.92 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN1B
16
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
17
Show member pathways
12.87 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
18
Show member pathways
12.83 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
19 12.76 CCND1 CDK6 CDKN1A CDKN1B CDKN2A MDM2
20
Show member pathways
12.73 CDK2 CDKN1A CDKN1B MDM2 TP53
21 12.73 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
22
Show member pathways
12.7 CCND1 CDKN1B MDM2 MYC RB1 TP53
23 12.69 CCND1 CDK4 CDKN1A CDKN2A IL2 MYC
24 12.68 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
25
Show member pathways
12.67 CCND1 MYC POU5F1 SOX2 TP53
26
Show member pathways
12.66 CCND1 CDKN1A CDKN1B MDM2 MYC TP53
27
Show member pathways
12.61 CCND1 CDK2 CDK4 CDK6 CDKN1B RB1
28
Show member pathways
12.59 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
29 12.54 CDK2 CDKN1A CDKN1B MDM2 MYC RB1
30
Show member pathways
12.53 CCND1 CDK2 CDK4 CDKN1A E2F4 MDM2
31
Show member pathways
12.5 CDK2 CDKN1A CDKN1B RB1 TP53
32 12.49 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
33 12.45 CCND1 CDKN1A MDM2 MYC TP53
34 12.45 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
35 12.44 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F4
36 12.43 BRCA2 CCND1 CDK2 CDK4 MDM2 MYC
37 12.41 CDKN1A CDKN1B MDM2 MYC TP53
38
Show member pathways
12.37 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
39 12.35 CCND1 CDKN1A E2F4 MYC TP53
40 12.35 CCND1 CDKN1A E2F4 MYC RBL1 RBL2
41
Show member pathways
12.32 CCND1 CDK2 CDKN1A CDKN1B MDM2 RBL2
42
Show member pathways
12.31 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
43
Show member pathways
12.3 CCND1 CDK4 E2F4 MYC RB1
44 12.3 CCND1 CDK2 CDK4 CDKN1B IL2 MYC
45 12.28 CDK2 CDKN1A CDKN2A MDM2 RB1 TP53
46
Show member pathways
12.28 CCND1 CDKN1A CDKN1B MDM2 MYC TP53
47 12.27 CCND1 CDKN1A CDKN1B CDKN2A MDM2 MYC
48 12.25 CDKN1A E2F4 RB1 RBL1 RBL2
49
Show member pathways
12.25 CCND1 CDK2 CDK4 CDK6 E2F4 MYC
50 12.23 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B

GO Terms for Ocular Cancer

Cellular components related to Ocular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.95 CDK4 CDKN1A CDKN2A MDM2 MYC RBL2
2 transcription factor complex GO:0005667 9.8 CDK2 CDK4 E2F4 RB1 RBL1 RBL2
3 nuclear chromatin GO:0000790 9.73 E2F4 MYC POU5F1 TP53
4 chromatin GO:0000785 9.67 CDK4 RB1 RBL1 RBL2
5 nucleoplasm GO:0005654 9.55 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
6 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.35 CCND1 CDK2 CDK4 CDK6 CDKN1A
7 cytosol GO:0005829 10.17 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
8 nucleus GO:0005634 10.13 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6

Biological processes related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.98 CDK2 CDK4 CDK6 MDM2 MYC POU5F1
2 negative regulation of cell growth GO:0030308 9.97 CDKN1A CDKN1B CDKN2A TP53
3 response to organic substance GO:0010033 9.95 CCND1 CDK2 CDK4 CDKN1A
4 negative regulation of gene expression GO:0010629 9.95 CDKN1A MDM2 MYC POU5F1 RB1 RBL1
5 regulation of mitotic cell cycle GO:0007346 9.93 CDKN1A MYC RB1 RBL1 RBL2
6 negative regulation of epithelial cell proliferation GO:0050680 9.91 CDK6 CDKN1B RB1 SOX2
7 Ras protein signal transduction GO:0007265 9.91 CDK2 CDKN1A CDKN2A RB1 TP53
8 regulation of G2/M transition of mitotic cell cycle GO:0010389 9.9 CDK2 CDK6 CDKN2A
9 response to wounding GO:0009611 9.89 MYC POU5F1 SOX2
10 cellular response to organic cyclic compound GO:0071407 9.89 CDKN1B MDM2 MYC
11 positive regulation of fibroblast proliferation GO:0048146 9.88 CDK4 CDK6 CDKN1A MYC
12 protein kinase B signaling GO:0043491 9.87 CDKN1A CDKN1B MDM2
13 animal organ regeneration GO:0031100 9.87 CCND1 CDK4 CDKN1A
14 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.87 CDKN1A RB1 RBL1 RBL2
15 regulation of cell cycle GO:0051726 9.87 CCND1 CDK2 CDK4 CDKN1A RB1 RBL1
16 negative regulation of cell cycle GO:0045786 9.86 CDK6 CDKN1B RB1
17 cell cycle arrest GO:0007050 9.86 CDK6 CDKN1A CDKN1B CDKN2A MYC RB1
18 response to gamma radiation GO:0010332 9.85 BRCA2 MYC TP53
19 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.84 BRCA2 CDKN1A TP53
20 cellular response to gamma radiation GO:0071480 9.84 CDKN1A MDM2 TP53
21 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.82 CDKN1A CDKN1B CDKN2A
22 negative regulation of cell cycle arrest GO:0071157 9.81 CCND1 CDK4 MDM2
23 negative regulation of phosphorylation GO:0042326 9.8 CDKN1A CDKN1B CDKN2A
24 response to X-ray GO:0010165 9.8 BRCA2 CCND1 CDKN1A TP53
25 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.79 BRCA2 CDKN1A TP53
26 replicative senescence GO:0090399 9.78 CDKN1A CDKN2A TP53
27 positive regulation of cell cycle GO:0045787 9.77 CCND1 CDK4 CDKN1B MDM2 MYC
28 cell cycle GO:0007049 9.77 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
29 mitotic G1 DNA damage checkpoint GO:0031571 9.75 CCND1 CDK2 TP53
30 cellular response to estrogen stimulus GO:0071391 9.73 MDM2 MYC
31 response to hyperoxia GO:0055093 9.73 CDK4 CDKN1A
32 response to magnesium ion GO:0032026 9.72 CCND1 MDM2
33 cellular response to antibiotic GO:0071236 9.72 CDKN1B MDM2
34 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.72 CDK4 CDK6 CDKN2A
35 amyloid fibril formation GO:1990000 9.71 CDKN2A MDM2
36 negative regulation of monocyte differentiation GO:0045656 9.71 CDK6 MYC
37 re-entry into mitotic cell cycle GO:0000320 9.7 CCND1 MYC
38 signal transduction by p53 class mediator GO:0072331 9.7 CDKN1A TP53
39 endodermal cell fate specification GO:0001714 9.7 POU5F1 SOX2
40 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.7 CDK4 MYC
41 regulation of lipid kinase activity GO:0043550 9.7 RB1 RBL1 RBL2
42 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.7 CDK2 CDKN1A CDKN1B E2F4 MDM2 RBL2
43 negative regulation of cyclin-dependent protein kinase activity GO:1904030 9.68 CDKN1A CDKN1B
44 cellular response to actinomycin D GO:0072717 9.68 MDM2 TP53
45 G1/S transition of mitotic cell cycle GO:0000082 9.28 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
46 transcription, DNA-templated GO:0006351 10.38 CCND1 CDKN2A E2F4 MYC POU5F1 RB1
47 regulation of transcription, DNA-templated GO:0006355 10.38 BRCA2 CCND1 CDKN2A E2F4 MYC POU5F1
48 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 CDKN2A E2F4 IL2 MYC POU5F1 RB1
49 phosphorylation GO:0016310 10.18 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
50 positive regulation of transcription, DNA-templated GO:0045893 10.17 BRCA2 CDK2 CDKN2A MYC RB1 SOX2

Molecular functions related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.91 CCND1 CDKN1A CDKN1B CDKN2A TP53
2 ubiquitin protein ligase binding GO:0031625 9.88 CDKN1A MDM2 POU5F1 RB1 TP53
3 transcription factor binding GO:0008134 9.7 CCND1 CDKN2A E2F4 MYC RB1 RBL1
4 RNA polymerase II activating transcription factor binding GO:0001102 9.67 RB1 RBL1 RBL2
5 promoter-specific chromatin binding GO:1990841 9.67 E2F4 RBL1 RBL2 TP53
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.61 CDKN1A CDKN1B CDKN2A
7 RNA polymerase II regulatory region DNA binding GO:0001012 9.58 RB1 RBL1 RBL2
8 disordered domain specific binding GO:0097718 9.56 CDKN2A MDM2 RB1 TP53
9 cyclin binding GO:0030332 9.35 CDK2 CDK4 CDK6 CDKN1A CDKN1B
10 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.1 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
11 protein binding GO:0005515 10.32 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
12 DNA binding GO:0003677 10.18 BRCA2 CDKN2A E2F4 MYC POU5F1 RB1
13 kinase activity GO:0016301 10 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B

Sources for Ocular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....